MeiraGTx (MGTX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual General Meeting scheduled for June 12, 2025, with voting open until June 11, 2025, at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 29, 2025.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of Thomas E. Shenk, Ph.D., as director is on the ballot.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Board recommends voting in favor of both proposals.
Additional business may be transacted as appropriate during the meeting.
Board of directors and corporate governance
Board has nominated Thomas E. Shenk, Ph.D., for election as director at the upcoming meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MeiraGTx
- Pivotal programs and riboswitch innovation accelerate cost-effective therapy development.MGTX
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Late-stage genetic medicine programs and the Riboswitch platform promise broad clinical impact.MGTX
Chardan's 8th Annual Genetic Medicines Conference20 Jan 2026 - Transformative gene therapies advance in rare blindness, xerostomia, and Parkinson's, with strong regulatory support.MGTX
RBC Inaugural Virtual Ophthalmology Conference26 Dec 2025 - All 11 children with LCA4 gained vision and developmental benefits after gene therapy.MGTX
Study Update23 Dec 2025 - Director election, auditor ratification, and key governance, compensation, and transactions detailed.MGTX
Proxy Filing2 Dec 2025 - Q3 2025 net loss rose to $50.5M; major partnerships support funding into 2027.MGTX
Q3 202513 Nov 2025 - Gene therapies show promise for neurodegenerative diseases, with strong efficacy and regulatory support.MGTX
Chardan’s 9th Annual Genetic Medicines Conference21 Oct 2025 - Q2 2025 loss narrowed as revenue rose and funding extended cash runway into 2027.MGTX
Q2 202514 Aug 2025 - Late-stage pipeline, transformative riboswitch technology, and strong partnerships drive growth.MGTX
Corporate Presentation3 Jul 2025